Location & dates EMBL Heidelberg, Germany 8 - 10 Dec 2019
Deadlines Registration closed Abstract submission closed
organiser_WGC

EMBL Courses and Conferences during the Coronavirus pandemic

With the onsite programme paused, many of our events are now being offered in virtual formats.


Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.


More information for participants of events at EMBL Heidelberg can be found here.

Programme

Got something to say? Tweet it! #EWGtarget

Day 1 - Sunday 8 December 2019
TimeSpeaker
14:00 - 15:00 Arrival and Registration
with light refreshments
15:00 - 15:15 Opening remarks
15:15 - 16:00

Keynote speaker
FinnGen: a public-private partnership to mine genomics and health data for new paths to therapy

Mark Daly - Institute for Molecular Medicine Finland FIMM, Finland

16:00 - 19:00 Session 1 - Genetics
Chair:
Jeff Barrett - Genomics plc, UK
16:00 - 16:30

Translating immune disease GWAS variants to causal cell types and genes
Gosia Trynka - Wellcome Sanger Institute, UK

16:30 - 16:45 Human loss-of-function variants in >4 million individuals suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson’s disease
Nicola Whiffin - Imperial College London, UK
16:45 - 17:00 Inhibition of angiotensinogen as a therapeutic strategy for lowering blood pressure: a Mendelian randomization study
Jonas Bovijn - University of Oxford, UK
17:00 -17:30 Big data meets drug discovery
Astrid Ruefli-Brasse - 23andMe, USA
17:30 - 18:00

Coffee Break and Meet the Speakers

18:00 - 18:30

Guiding targets to success: Experiences progressing genetically validated targets through discovery and development
Janna Hutz - Eisai Center for Genetics Guided Dementia Discovery, USA

18:30 - 18:45 Evaluating genetic support for lipid-modifying drug targets
Maria - Gordillo-Maranon, University College London, UK
18:45 - 19:00

A phenome-wide gene-based collapsing analysis of rare loss-of-function and missense variation in 136,508 UK Biobank exomes
Slavé Petrovski - AstraZeneca, UK

19:00 - 20:00

Dinner

20:00 - 22:00

Poster Session 1 (odd numbers)

Day 2 - Monday 9 December 2019
TimeSpeaker
09:00 - 12:00 Session 2 - Case studies
Chair:
Sandra Engle - Biogen, USA
09:00 - 09:30 Functional genetics and genomics cross-comparisons between immune-mediated diseases
Calliope Dendrou - Wellcome Trust Centre for Human Genetics, UK
09:30 - 10:00 From SNPs to biology in autoimmune disease                      
James Lee - University of Cambridge, UK
10:00 - 10:15 A cross-disciplinary, integrative approach to target prioritization
Katrina de Lange - Novartis, Switzerland
10:15 - 10:30

Identification of a candidate for breast cancer risk prevention
Jonathan Beesley- QIMR BERGHOFER, Australia

10:30 - 11:00

Coffee Break and Meet the Speakers

11:00 - 11:30 Genomics and Target Validation in Alzheimer's disease
Damien Crowther - AstraZeneca, UK
11:30 - 11:45 Investigating the causal relationship between glaucoma and Alzheimer’s disease: a mendelian randomization study
Ashley Budu-Aggrey- University of Bristol, UK
11:45 - 12:00 Investigating calcium channel isoforms to identify novel, genomically-informed treatment targets for psychiatric disorders
Nicola Hall - University of Oxford, UK
12:00 - 13:30

Lunch

13:30 - 16:30 Session 3 - Genome editing for target validation
Chair:
Gitte Neubauer - Cellzome, Germany
13:30 - 14:00 Advanced CRISPR applications in primary human T cells
Eric Shifrut - University of California, San Francisco, USA
14:00 - 14:15 Unbiased compound-target interface mapping by forward genetics
Moritz Horn - Acus Laboratories GmbH, Germany
14:15 - 14:30 Target discovery through functionall genomics
Samantha Peel - Astrazeneca, UK
14:30 -15:00

Modeling disease biology with human stem cell-derived cells and genomic editing to enable drug discovery
Sandra Engle - Biogen, USA

15:00 -15:30

Coffee Break and Meet the Speakers

15:30 -16:00 Mapping gene regulation with large-scale cellular genetic screens
Silvia Domcke - University of Washington, USA
16:00 - 16:15 CRISPR/Cas9 functional screens for long non-coding RNAs in lung cancer
Taisia Polidori - University of Bern, Switzerland
16:15 -16:30 Functional insights and enhanced target identification through co-essentiality
Martino Colombo - Celgene Research, Spain
16:30 - 18:30 Poster Session 2 (even numbers)
18:45 Buses depart to Christmas market and hotels
Day 3 - Tuesday 10 December 2019
TimeSpeaker
09:00 - 11:45 Session 4 - Relevant models for target validation
Chair:
Gosia Trynka - Wellcome Sanger Institute, UK
09:00 - 09:30 Understanding mechanisms of resistance: novel targets for cancer treatment
Dirk Jäger - National Center for Tumor Diseases, Germany
09:30 - 09:45 Functional genomic follow-up of GWAS to identify novel drug targets for endometrial cancer
Dylan Glubb - QIMR Berghofer Medical Research Institute, Australia
09:45 - 10:00 Functional genomic analysis uncovers mitophagy regulators associated with Parkinson’s disease risk
Daniela Melandri - University College London, UK
10:00 - 10:30

Organoid biobanks combine genetic and functional patient and disease data
Robert Vries - Hubrecht Organoid Technology, The Netherlands

10:30 - 11:00 Coffee Break and Meet the Speakers
11:00 - 11:15 Systematic prioritisation of genes at all GWAS trait-associated loci
Edward Mountjoy - Wellcome Sanger Institute, UK
11:15 - 11:45 Learning the manifold of human disease with the aim to establish a new approach to drug discovery
Paolo Casale - insitro, USA
11:45 - 13:15

Lunch

13:15- 16:15 Session 5 - Computational methods and analysis
Chair: 
Oliver Stegle - EMBL Heidelberg, Germany
13:15 - 13:45 Using genomics to evaluate T-cell therapeutic targets
Hans Bitter - bluebird bio, USA
13:45 - 14:00 Genetic drug target validation using Mendelian randomization
Amand Schmidt - University College London, UK
14:00 - 14:15 Network and pathway analysis of GWAS for target identification
Alex Gutteridge - GSK, UK
14:15 - 14:45 Therapeutic target identification through the inference of pathogenic cells and tissues
Jeff Barrett - Genomics plc, UK
14:45 - 15:15 Coffee Break and Meet the Speakers
15:15 - 15:30 Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets
Hendrik Weisser - STORM Therapeutics, UK
15:30 - 15:45 Reconciling GWAS and Mendelian genetics through core-gene identification
Patrick Deelen - University Medical Center Groningen, The Netherlands
15:45 - 16:30 Keynote speaker
Relevant phenotypic screens in complex systems

Edith Hessel - GSK, UK
16:30 - 16:45 Closing remarks and poster prize
17:00 Buses depart to downtown and airport